



Noted Cleveland Clinic Cardiologist to Join VentriPoint Scientific Advisory Board

SEATTLE, WASHINGTON, May 5, 2011 – VentriPoint Diagnostics Ltd. ("VentriPoint") (TSXV:VPT; Pink OTC:VPTDF.PK) is pleased to announce that Dr. Richard Krasuski, Director of Adult Congenital Heart Disease Services at the world renowned Cleveland Clinic's Sydell and Arnold Miller Family Heart and Vascular Institute, has agreed to join the Company's Scientific Advisory Board.

"Dr. Krasuski has an extensive clinical background in pulmonary hypertension, and we are fortunate to benefit from his expert advice as we expand the VMS™ applications for diagnostic care to include this serious condition", commented Dr. George Adams, VentriPoint's CEO.

Dr. Krasuski has been very supportive of the VMS™.

Dr. Krasuski received his undergraduate degree from Bowdoin College in Maine (Phi Beta Kappa) and his medical degree from Harvard Medical School. He completed his residency in internal medicine at Brigham & Women's Hospital in Boston, followed by a fellowship in cardiology at Duke University Medical Center in North Carolina, which included a subspecialty in valvular heart disease and adult congenital heart disease.

Dr. Krasuski has served as an abstract reviewer for the American College of Cardiology and has chaired various oral sessions in the past. Presently, he is a reviewer for several leading medical publications including *Circulation*, the *American Journal of Cardiology*, *Annals of Internal Medicine*, *Heart*, *American Journal of Managed Care*, *American Journal of Medicine*, and the *American Heart Journal*. Dr. Krasuski is a Fellow both of the American College of Cardiology (FACC) and the American Heart Association (FAHA), and a member of the Adult Congenital Heart Association, the International Society for Adult Congenital Heart Disease, the Pulmonary Hypertension Clinicians and Researchers Society of the Pulmonary Hypertension Association and the Massachusetts Medical Society.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. The VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion-dollar



market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ diagnostic tool and it is pursuing the US-FDA approval through the 510(k) process.

For further information, please contact:

VentriPoint Diagnostics Ltd.

Dr. George Adams, CEO
Telephone: (206) 283-0221, ext. 401
email: gadams@ventripoint.com

Howard Group Inc.

Peter Weichler/David Burwell
Telephone: 1.888-221-0915 or 403-221-0915
email: Peter@howardgroupinc.com
Dave@howardgroupinc.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.